Trial intelligence / Profile preview

Phase II adjuvant S-1 with concurrent radiotherapy after pancreatic cancer resection in high-risk patients

ChiCTR-ONC-13003060Phase 2Recruiting

Sponsor
Zhongshan Hospital, Fudan University
Start
Jan 2013
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of tegafur in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Overall survival. Started Jan 2013; status: recruiting.

02

Drugs

tegafur
03

Conditions

pancreatic cancer (PC)

Beyond the preview

Go deeper on ChiCTR-ONC-13003060.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-ONC-13003060.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call